On August 25, 2020 Shenzhen Yuce Biological reported that completed a $43 million Series C round led by Yuanzhi Science & Technology Medical for its clinical testing of cancer immunotherapies (Press release, Shenzhen Yuce Biotechnology, AUG 25, 2020, View Source [SID1234564010]). Yuce Bio has developed a new antigen detection and identification platform, a professional database for cancer immunology based on bioinformatics, and a large real-world research database of tumor immunodiagnosis. As part of its program, Yuce has developed YuceOne Plus, the first in vitro diagnostic reagent that uses gene testing to evaluate the effectiveness of an immunotherapy drug regimen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 25, 2020 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, reported that it will report financial results for the first quarter of fiscal year 2021 on September 1, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time) (Press release, Avid Bioservices, AUG 25, 2020, View Source [SID1234564009]). Members of Avid’s senior management will discuss financial results for the first quarter and review recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast, or access the archived webcast, please visit: View Source

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.

On August 25, 2020 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host virtual one-on-one meetings at the Barclay’s Global Consumer Staples Conference on Wednesday, September 9, 2020 (Press release, Perrigo Company, AUG 25, 2020, View Source [SID1234564008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Also, Mr. Kessler will present at the 18th Annual Morgan Stanley Global Healthcare Conference at 8:45 am EST on Thursday, September 17, 2020. Interested parties can access the presentation webcast at View Source

On August 25, 2020 OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer will present at the LD 500 Virtual Conference on Wednesday, September 2, 2020 (Press release, OncoSec Medical, AUG 25, 2020, View Source/press-releases/detail/2060/oncosec-to-present-at-the-ld-500-virtual-conference-on" target="_blank" title="View Source/press-releases/detail/2060/oncosec-to-present-at-the-ld-500-virtual-conference-on" rel="nofollow">View Source [SID1234564000]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will begin September 2, 2020 at 10:00 a.m. eastern time, Track 3, followed by a live Q&A session with registered investors and other conference attendees. The OncoSec presentation will be webcast at View Source, and will be available on the Investors section of OncoSec’s website, View Source, where it will be archived for approximately 30 days.

The virtual conference and presentations will be held via webcast from September 1 – 4, 2020 and Mr. O’Connor will be available for virtual one-on-one meetings throughout. To schedule a meeting, please contact Eric Lahiji at [email protected].

On August 25, 2020 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer, will be presenting at the LD Micro 500 Virtual Investor Conference on September 1, 2020 at 9:40 am Eastern Time / 6:40 am Pacific Time (Press release, Lineage Cell Therapeutics, AUG 25, 2020, View Source [SID1234563999]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Brian M. Culley and Brandi L. Roberts, Chief Financial Officer, will also be participating in the 2020 Solebury Trout Zoomside Chat on September 1, 2020 at 12:00 pm Eastern Time / 9:00 am Pacific Time. The Solebury Trout conference format will consist of fireside chats between participating companies and covering analysts. Lineage management will participate in a fireside chat hosted by Joseph Pantginis, Ph.D., Managing Director, Equity Research, H.C. Wainwright & Co., LLC.

Interested investors can access both live presentations on the Events and Presentations section of Lineage’s website and archived presentations will be available for 30 days. Additional videos are available on the Media page of the Lineage website, located at www.lineagecell.com/media/.